DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Verelan (Verapamil Hydrochloride) - Published Studies


Verelan Related Published Studies

Well-designed clinical trials related to Verelan (Verapamil)

Need for prophylactic application of verapamil in transradial coronary procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial Interventions OmittabLe?) trial. [2014]

Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]

Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. [2011.08]

Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension. [2011.06]

The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. [2011.06]

A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. [2011.02.01]

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. [2011.02]

Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). [2010.12]

Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. [2010.11.15]

The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, and verapamil on the cardiovascular influences of dexmedetomidine in conscious sheep. [2010.10]

Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). [2010.08.15]

Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease. [2010.04]

Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. [2010.03]

Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma. [2009.11]

Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. [2009.07]

Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. [2009.06]

Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. [2009.05]

Impact of nitroglycerin and verapamil on coronary arterial distensibility as assessed by intravascular ultrasound. [2009.04]

Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. [2009]

Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. [2008.12]

The effect of oral verapamil on the visual evoked potentials in multiple sclerosis patients. [2008.09]

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). [2008.08]

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]

Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study. [2008]

Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. [2007.11]

Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. [2007.08]

Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). [2007.06.01]

Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. [2007.05]

Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03.01]

Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. [2007.03]

Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. [2007.03]

Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. [2007.03]

Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. [2007.01]

Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. [2006.11.15]

Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). [2006.10.01]

Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. [2006.09.05]

Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. [2006.09]

Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. [2006.08]

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. [2006.08]

Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. [2006.04]

Effects of papaverine and glycerilnitrate-verapamil solution as topical and intraluminal vasodilators for internal thoracic artery. [2006.01]

Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. [2005.11]

Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. [2005.11]

Assessment of the efficacy of phentolamine to prevent radial artery spasm during cardiac catheterization procedures: a randomized study comparing phentolamine vs. verapamil. [2005.10]

A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker. [2005.09.15]

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]

Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. [2005.07]

Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. [2005.05]

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. [2005.01]

Well-designed clinical trials possibly related to Verelan (Verapamil)

Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. [2011.10]

Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011? [2011.08]

Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men. [2011.04.26]

Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. [2011.04]

Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). [2010.12.08]

Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]

The effects of ritodrine and magnesium sulfate on maternal and fetal Doppler blood flow patterns in women with preterm labor. [2010.09]

Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans. [2010.08.05]

Acute and preventive pharmacologic treatment of cluster headache. [2010.08.03]

Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. [2010.08]

Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. [2010.08]

Impaired vascular function after exposure to diesel exhaust generated at urban transient running conditions. [2010.07.23]

Exposure to nitrogen dioxide is not associated with vascular dysfunction in man. [2010.02]

Therapeutic window for calcium-channel blockers in the management of dilated cardiomyopathy: a prospective, two-centre study on non-advanced disease. [2010]

Acute and preventive pharmacologic treatment of cluster headache. [2010]

Systolic blood pressure and subjective well-being in patients with coronary artery disease. [2009.11]

Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. [2009.09]

Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. [2009.07]

Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. [2009.05]

Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. [2009.05]

Differential effects of calcium-channel blockers on vascular endothelial function in patients with coronary spastic angina. [2009.04]

N-terminal-pro-B-type natriuretic peptide during pharmacological heart rate reduction in hyperthyroidism. [2009.04]

Bedtime versus at awakening administration of BP lowering drugs--is it the way to success? [2009]

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. [2008.12]

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. [2008.12]

Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. [2008.10]

Comparison of rate and rhythm control in hypertension patients with atrial fibrillation. [2008.05]

Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. [2008.01]

Differential index: a simple time domain heart rate variability analysis with prognostic implications in stable angina pectoris. [2008]

Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring. [2007.12]

Comparative study of nicorandil and a spasmolytic cocktail in preventing radial artery spasm during transradial coronary angiography. [2007.09.03]

Persistent endothelial dysfunction in humans after diesel exhaust inhalation. [2007.08.15]

Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. [2007.04.17]

Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. [2007]

Prognostic implications of renal dysfunction in patients with stable angina pectoris. [2006.12]

Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. [2006.12]

Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. [2006.10.21]

Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. [2006.08]

Prevention of arterial spasm during percutaneous coronary interventions through radial artery: the SPASM study. [2006.08]

Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? [2006.06.20]

Adenosine cardioprotection study in clinical setting of paroxysmal supraventricular tachycardia. [2006.06]

The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. [2006.06]

Depressive symptoms in coronary artery disease patients after hypertension treatment. [2006.04]

Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model. [2006.03]

Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). [2006.02]

Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. [2006.02]

Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. [2006.01]

Heart rate slowing versus other pharmacological antianginal strategies. [2006]

A simple and effective regimen for prevention of radial artery spasm during coronary catheterization. [2006]

Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. [2005.12.20]

Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. [2005.12]

Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. [2005.08]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017